# ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

> **NCT04143607** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu Aosaikang Pharmaceutical Co., Ltd.** · enrollment: 337 (actual)

## Conditions studied

- Locally Advanced or Metastatic NSCLC

## Interventions

- **DRUG:** ASK120067
- **DRUG:** Placebo Gefitinib 250 mg
- **DRUG:** Gefitinib
- **DRUG:** Placebo ASK120067

## Key facts

- **NCT ID:** NCT04143607
- **Lead sponsor:** Jiangsu Aosaikang Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-23
- **Primary completion:** 2024-03-31
- **Final completion:** 2026-09-30
- **Target enrollment:** 337 (ACTUAL)
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04143607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04143607, "ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04143607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*